Pre-Clinical RA - Clinical Trial Outcomes
Pivotal Trials in at-risk patients.
Oral Surveillance study resulted in a new FDA drug safety bulleting 9/21/21 and since the label for all JAK inhibitors has changed (FDA, Canada) or will change (EMA).
Use this resource to keep track of your clinical trials and key information needed when communicating with patients about a drug study.
Outcomes, misdiagnosis, diagnosis, Diagnostic criteria and treatmenet options for AOSD
Handouts to Dr. Len Calabreses TNR Presentation
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.